Skip to main content
. 2016 Dec 31;109(2):djw248. doi: 10.1093/jnci/djw248

Figure 2.

Figure 2.

Proposed strategy for developing the next generation of clinical trials in T-cell lymphoma (TCL). A) Relapsed disease with representative examples. B) Frontline setting with representative examples. C) Clinical trials in TCL that include a putative biomarker (as an example, CD30). TCL = T-cell lymphoma.

HHS Vulnerability Disclosure